Areas of expertise
We understand the science of value
You have goals. We have experience to reach them.
Health economics and outcomes research
From complementing your in-house HEOR experts to conducting research and analysis on your behalf, our global HEOR capabilities are tailored to fit your needs.
Commercialize products and launch strategies
Gain insights into the payer mindset and translate evidence into powerful messages and strategic plans that distinguish your brand for successful product launch.
Innovative field solutions
Overcome barriers to patient access and optimize relationships between provider, patient hub, and payer with the pioneers in field reimbursement.
Generate robust real-world evidence across a wide spectrum of criteria with our data-driven solutions that prove product value and maximize patient access.
Global market access consulting
Whether you need insights from payers, providers, or patients, our experts create customized engagements that tap into the minds of critical stakeholders.
Health Policy Weekly
Stay on top of legislative changes, regulatory developments, and healthcare reform news that impacts pharmaceutical, biotech, and device manufacturers, as well as providers and managed care professionals.
Our featured areas include:
We’re built to help you navigate the complex decisions related to oncology product development and commercialization. We have worked with more than 250 different brands supporting clients, collaborating on over 2000 oncology projects.
Cell and gene therapy
Ready to transform patient outcomes in this clinically promising yet commercially challenging new frontier in medicine? Let us help. We’ve commercialized every cell and gene therapy launched in the U.S.
From supporting the first U.S. biosimilar to conducting landmark coding and reimbursement research, we are a trusted leader in the biosimilars market. Let us help you gain centralized access to FDA guidance on biosimilars and substitution laws for all 50 states.
Rare diseases and orphan products
Small patient populations face monumental challenges in rare disease states. Manufacturers are often left with information gaps that need to be addressed. From data, studies, education, and access, let us conquer the unmet needs for your most specialized therapies.
Helping your therapeutic innovations thrive
Stay on top of an evolving landscape
Proactively position for value-based care
Understanding how payers evaluate products is key as the value-based landscape evolves. Gain insights into a wide array of methodologies and frameworks to present the most salient evidence required to survive the scrutiny.
Translate new HCEI guidance for maximum opportunity
The 21st Century Cures Act has given greater clarity to FDAMA 114, allowing new possibilities for pre-approval and proactive payer communication. Develop a strategy and suite of tools that embraces the new standards to favorably position your product in the minds of key stakeholders.
Start a conversation
We’re value drivers and problem solvers. Let us connect you with experts who understand your world and what success demands.